Tremfya

Janssen tackles racial gap in Phase IIIb psoriasis trial with Tremfya
Janssen tackles racial gap in Phase IIIb psoriasis trial with Tremfya
Clinical Trials Arena
Janssen
psoriasis
Tremfya
clinical trials
Flag link:
Janssen’s Tremfya maintains three years of remission in Phase II Crohn’s disease trial
Janssen’s Tremfya maintains three years of remission in Phase II Crohn’s disease trial
Clinical Trials Arena
JNJ
Janssen
clinical trials
Crohn's Disease
Tremfya
Flag link:
Johnson & Johnson’s Tremfya outshines IL-17 inhibitors as plaque psoriasis treatment
Johnson & Johnson’s Tremfya outshines IL-17 inhibitors as plaque psoriasis treatment
Clinical Trials Arena
JNJ
Janssen
Tremfya
psoriasis
real world data
Flag link:
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
Flag link:
New TREMFYA Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
New TREMFYA Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
Marketscreener
JNJ
Janssen
clinical trials
ulcerative colitis
Tremfya
Flag link:
Janssen Presents New Data that could Set Anti-Inflammatory Drug Apart
Janssen Presents New Data that could Set Anti-Inflammatory Drug Apart
BioSpace
JNJ
Janssen
Tremfya
Skyrizi
AbbVie
anti-inflammatories
Flag link:
J&J lands Tremfya one-two punch in IBD with first ulcerative colitis win and long-term Crohn's data
J&J lands Tremfya one-two punch in IBD with first ulcerative colitis win and long-term Crohn's data
Fierce Pharma
JNJ
Janssen
Tremfya
Crohn's Disease
Flag link:
J&J touts Tremfya win in Humira-resistant psoriatic arthritis patients amid showdown with AbbVie's Skyrizi
J&J touts Tremfya win in Humira-resistant psoriatic arthritis patients amid showdown with AbbVie's Skyrizi
Fierce Pharma
JNJ
Tremfya
psoriatic arthritis
AbbVie
Skyrizi
Flag link:
Janssen's Psoriatic Arthritis Drug Proves Long-Term Efficacy in Two-Year Trial
Janssen's Psoriatic Arthritis Drug Proves Long-Term Efficacy in Two-Year Trial
BioSpace
JNJ
Janssen
clinical trials
Tremfya
psoriatic arthritis
Flag link:
Janssen’s Tremfya gets FDA approval for active psoriatic arthritis
Janssen’s Tremfya gets FDA approval for active psoriatic arthritis
Pharmaceutical Business Review
Janssen
JNJ
FDA
Tremfya
psoriatic arthritis
Flag link:
Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data
Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data
Fierce Pharma
JNJ
Tremfya
psoriatic arthritis
psoriasis
clinical trials
Flag link:
J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis
J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis
BioSpace
JNJ
Janssen
Tremfya
clinical trials
psoriasis
Flag link:
J&J filing aims Tremfya at crowded psoriatic arthritis market
J&J filing aims Tremfya at crowded psoriatic arthritis market
Pharmaforum
JNJ
psoriatic arthritis
Tremfya
Flag link:
Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt
Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt
Fierce Pharma
Eli Lilly
Taltz
JNJ
Tremfya
psoriasis
Flag link:
Janssen’s guselkumab succeeds in phase 3 psoriatic arthritis trials
Janssen’s guselkumab succeeds in phase 3 psoriatic arthritis trials
Pharmaceutical Business Review
JNJ
Janssen
Tremfya
clinical trials
psoriatic arthritis
Flag link:
Janssen Eyes Another Approval for Tremfya After Hitting Trial Endpoints
Janssen Eyes Another Approval for Tremfya After Hitting Trial Endpoints
BioSpace
JNJ
Janssen
clinical trials
Tremfya
psoriatic arthritis
Flag link:
Novartis Sues Janssen Over False Advertisements for Psoriasis Drug
Novartis Sues Janssen Over False Advertisements for Psoriasis Drug
RAPS.org
Novartis
Janssen
JNJ
psoriasis
false advertising
Tremfya
Flag link:
Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod
Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod
Fierce Pharma
JNJ
Janssen
Tremfya
psoriasis
Novartis
Cosentyx
Eli Lilly
Taltz
Flag link:
FDA approves J&J’s Tremfya self-injection pen for psoriasis
FDA approves J&J’s Tremfya self-injection pen for psoriasis
Drug Delivery Business News
JNJ
FDA
Tremfya
psoriasis
Flag link:
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis
Fierce Pharma
JNJ
JPMHC 2019
immunology
psoriasis
Tremfya
Flag link:

Pages